This is a major de-risking event that confirms DT120 ODT's efficacy across multiple Phase 3 trials, significantly increasing the probability of NDA approval. Traders should watch for the pre-NDA meeting in Q4 2026 and the NDA filing in H1 2027 as the next key catalysts. The strong cash runway into 2030 removes near-term financing risk.
Price Chart
Executive Summary
Definium Therapeutics announced positive topline results from its Phase 3 Panorama study of DT120 ODT in generalized anxiety disorder (GAD). The study met its primary endpoint with a statistically significant 5.1-point placebo-adjusted reduction in HAM-A score at Week 12 (p<0.0001, Cohen's d=0.64), and all key secondary endpoints were also met. This is the third positive Phase 3 readout for DT120 ODT, and the company is advancing toward a pre-NDA meeting in Q4 2026 with an NDA filing anticipated in H1 2027, which is a major de-risking event for the stock.
Key Facts
- Panorama met its primary endpoint: 5.1-point placebo-adjusted HAM-A reduction at Week 12 (p<0.0001, Cohen's d=0.64).
- All key secondary endpoints were met, including CGI-S at Week 12 and Day 2, and HAM-A at Week 1 (all p<0.0001).
- DT120 ODT 100 µg was generally well-tolerated with no new safety signals; no drug-related serious adverse events or suicidality signal.
- This is the third positive Phase 3 readout for DT120 ODT, following positive results in MDD (Emerge) and GAD (Voyage).
- Pre-NDA meeting scheduled for Q4 2026; NDA filing anticipated in H1 2027.
- Cash, cash equivalents, and investments of ~$1.1 billion as of June 30, 2026, with runway expected into 2030.
Financial Impact
No financial figures reported in the filing. The company has ~$1.1 billion in cash, cash equivalents, and investments as of June 30, 2026.
Risk Factors
- Regulatory risk: DT120 ODT contains a Schedule I controlled substance (LSD), requiring DEA rescheduling before commercialization.
- Commercialization risk: The drug requires in-clinic administration with 6-8 hour monitoring sessions, which may limit adoption.
- Potential functional unblinding: 95% of participants in the 100 µg arm correctly guessed their treatment assignment, which could introduce bias.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-107275 |
| Document: tm2625365d1_ex99-1.htm | 0001104659-26-107275 |
| Document: tm2625365d1_8k.htm | 0001104659-26-107275 |
| Document: 0001104659-26-107275-index-headers.html | 0001104659-26-107275 |
| Document: 0001104659-26-107275-index.html | 0001104659-26-107275 |
| Document: 0001104659-26-107275.txt | 0001104659-26-107275 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $40.25 $39.28 | ▼ −2.41% | ▼ −2.52% | $37.40 (−7.08%) |
Aug 12, 2026 7w ago | 8-K | $42.79 $45.82 | ▲ +7.08% | ▲ +7.53% | $37.40 (−12.60%) |
Aug 9, 2026 7w ago | Institutional Cluster | $45.15 $45.26 | ▲ +0.24% | ▲ +0.29% | $37.40 (−17.17%) |
Jun 25, 2026 14w ago | 144 | $44.95 $44.19 | ▼ −1.69% | ▼ −3.86% | $37.40 (−16.80%) |
Jun 25, 2026 14w ago | 144 | $44.95 $44.19 | ▼ −1.69% | ▼ −3.86% | $37.40 (−16.80%) |
Jun 24, 2026 14w ago | 8-K | $44.79 $43.40 | ▲ +3.10% | ▲ +4.66% | $37.40 (+16.50%) |
Jun 24, 2026 14w ago | 424B5 | $44.79 $43.40 | ▲ +3.10% | ▲ +4.66% | $37.40 (+16.50%) |
Jun 22, 2026 14w ago | 424B5 | $36.18 $46.55 | ▼ −28.66% | ▼ −27.65% | $37.40 (−3.37%) |
Apr 27, 2026 22w ago | DEFA14A | $21.27 $21.75 | ▲ +2.26% | ▲ +0.56% | $37.40 (+75.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access